# Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

> **NCT03994913** · PHASE1,PHASE2 · COMPLETED · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed B-cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CAR-CD19 T Cells

## Key facts

- **NCT ID:** NCT03994913
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-14
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-05-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994913, "Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03994913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*